Surgical and oncological results of radical prostatectomy: experience of 7 years at the Hospital General de Occidente


ABSTRACT
Background: Prostate cancer is the principal cancer diagnosis in men and the second cause of death by cancer in men in the United States. It is in 4th place worldwide in frequency but corresponds to only 9% of all cancer-specific deaths in men. Radical prostatectomy is the most widely used therapy for the treatment of organ-confined disease and in select cases of nodular disease or its possibility. It is considered to be the criterion standard in relation to other alternatives such as radiotherapy, brachytherapy, high-intensity focused ultrasound, and watchful waiting.

Objective: To demonstrate the experience in the authors’ hospital department in prostate cancer treatment and to report the similarity of results with published standards in relation to surgical outcome and oncological disease follow-up.

Results: A total of 80 patients that underwent radical prostate surgery were evaluated. Mean age was 61.5 years (46-74 year range), mean surgery duration was 250 minutes, patients requiring transfusion was 40%, patients requiring 1 transfusion bag was 80%, 2 transfusion bags...
Conclusions: patients was related specifically to prostate cancer.

specific antigen above 1.5 ng/mL. The death of one of

failure, but only 2 patients continued to have prostate

prostate specific antigen, 25% reached biochemical

that figure. At five years, 75% of patients had unchanged

antigen values under 0.4 ng/mL and 20% were over

year of follow-up 80% of patients had prostate specific

was seen with scintigram in one patient. In the fourth

specific antigen above 1.5 ng/mL and bone metastases

10% in biochemical failure, two patients had prostate

during the first year 92% of patients continued to have prostate

specific antigen values under the nadir and 8% had

biochemical recurrence. The second year the change

was slight in which prostate specific antigen value in

90% of patients did not go above the nadir and 10%

continued in biochemical failure but under 1.5 ng/mL.

In the third year of follow-up, prostate specific antigen

of 90% of patients continued under the nadir but of the

10% in biochemical failure, two patients had prostate

specific antigen above 1.5 ng/mL and bone metastases

was seen with scintigram in one patient. In the fourth

year of follow-up 80% of patients had prostate specific

antigen values under 0.4 ng/mL and 20% were over

that figure. At five years, 75% of patients had unchanged

prostate specific antigen, 25% reached biochemical

failure, but only 2 patients continued to have prostate

specific antigen above 1.5 ng/mL. The death of one of

those patients was related specifically to prostate cancer.

Key words: Prostate cancer, treatment, complications.

20%, mean hospital stay was 72 hours, intraoperative

hemorrhage was 280-1500 cc, deep vein thrombosis

incidence was 3%, pulmonary thromboembolism was

1.25% and there was 1 death. The most prevalent

preoperative or diagnostic prostate specific antigen was

6.2 ng/mL. Transrectal biopsy of the prostate Gleason

score was 3+3, positive lymph node suspicion was 7.5%

in patients according to Partin, predominant Gleason

score in surgical specimen was 3+2, and 5% of specimens

had positive margins. There was correlation between

transrectal biopsy of the prostate and final specimen

Gleason scores in only 27% of cases. Postoperative

prostate specific antigen was underestimated in 31% of

patients and overestimated in 42%. In the first year 92%

of patients had postoperative prostate specific antigen

under 0.4 ng/mL and 8% did not reach that nadir. During

the first year 92% of patients continued to have prostate

specific antigen values under the nadir and 8% had

biochemical recurrence. The second year the change

was slight in which prostate specific antigen value in

90% of patients did not go above the nadir and 10%

continued in biochemical failure but under 1.5 ng/mL.

In the third year of follow-up, prostate specific antigen

of 90% of patients continued under the nadir but of the

10% in biochemical failure, two patients had prostate

specific antigen above 1.5 ng/mL and bone metastases

was seen with scintigram in one patient. In the fourth

year of follow-up 80% of patients had prostate specific

antigen values under 0.4 ng/mL and 20% were over

that figure. At five years, 75% of patients had unchanged

prostate specific antigen, 25% reached biochemical

failure, but only 2 patients continued to have prostate

specific antigen above 1.5 ng/mL. The death of one of

those patients was related specifically to prostate cancer.

Conclusions: Radical prostate surgery at the authors’

hospital is the most widely used treatment for organ-

confined disease. Reproducibility and perfection of this

technique have resulted in tangible improvements in

surgical results (shorter hospital stay, intraoperative

and perioperative complication reduction, improved

vascular control and thus lower blood transfusion rate

and a reduction in intraoperative hemorrhage) as well as

in oncological results that are reflected in better patient

selection, positive margin reduction, and early identification of high risk patients for metastatic

progression or nodular disease.

Key words: Prostate cancer, treatment, complications.

Conclusions: The surgical and oncological results of radical prostatectomy: experience of 7 years at the Hospital General de Occidente

20%, mean hospital stay was 72 hours, intraoperative

hemorrhage was 280-1500 cc, deep vein thrombosis

incidence was 3%, pulmonary thromboembolism was

1.25% and there was 1 death. The most prevalent

preoperative or diagnostic prostate specific antigen was

6.2 ng/mL. Transrectal biopsy of the prostate Gleason

score was 3+3, positive lymph node suspicion was 7.5%

in patients according to Partin, predominant Gleason

score in surgical specimen was 3+2, and 5% of specimens

had positive margins. There was correlation between

transrectal biopsy of the prostate and final specimen

Gleason scores in only 27% of cases. Postoperative

prostate specific antigen was underestimated in 31% of

patients and overestimated in 42%. In the first year 92%

of patients had postoperative prostate specific antigen

under 0.4 ng/mL and 8% did not reach that nadir. During

the first year 92% of patients continued to have prostate

specific antigen values under the nadir and 8% had

biochemical recurrence. The second year the change

was slight in which prostate specific antigen value in

90% of patients did not go above the nadir and 10%

continued in biochemical failure but under 1.5 ng/mL.

In the third year of follow-up, prostate specific antigen

of 90% of patients continued under the nadir but of the

10% in biochemical failure, two patients had prostate

specific antigen above 1.5 ng/mL and bone metastases

was seen with scintigram in one patient. In the fourth

year of follow-up 80% of patients had prostate specific

antigen values under 0.4 ng/mL and 20% were over

that figure. At five years, 75% of patients had unchanged

prostate specific antigen, 25% reached biochemical

failure, but only 2 patients continued to have prostate

specific antigen above 1.5 ng/mL. The death of one of

those patients was related specifically to prostate cancer.

Conclusions: Radical prostate surgery at the authors’

hospital is the most widely used treatment for organ-

confined disease. Reproducibility and perfection of this

technique have resulted in tangible improvements in

surgical results (shorter hospital stay, intraoperative

and perioperative complication reduction, improved

vascular control and thus lower blood transfusion rate

and a reduction in intraoperative hemorrhage) as well as

in oncological results that are reflected in better patient selection, positive margin reduction, and early identification of high risk patients for metastatic

progression or nodular disease.

Key words: Prostate cancer, treatment, complications.

Conclusions: La cirugía radical de la próstata ha de-

mostrado en nuestro centro ser la terapia más utilizada

en el tratamiento de la enfermedad órgano confinada. La

reproductibilidad de esta técnica y el perfeccionamiento

de la misma, ha permitido mejoras tangibles tanto en

los resultados quirúrgicos (menor estancia intrahospita-

laria, reducción de la tasa de complicaciones trans y peri

operatorias, mejor control vascular y por lo tanto, menor

tasa hemotransfusional y disminución de la hemorragia

transoperatoria), así como en los resultado oncológicos,

que se reflejan en: una mejor selección de los pacientes,

reducción de los márgenes positivos, identificación tem-

prana de los pacientes de alto riesgo para la progresión

metástásica o de enfermedad nodular de los pacientes.

Palabras clave: Cáncer de próstata, tratamiento, com-

plicaciones, México.
There is no clinical evidence and there are no randomized, double-blind studies that compare surgical treatment with other therapeutic alternatives for prostate cancer (CaP). The guidelines put out by the American Urological Association (AUA) and the European Urological Association (EUA) suggest that radical prostatectomy, in any of its modalities, is the alternative that offers the most surgical tumor control by removing the entire prostate, and when necessary, the lymphatic chains involved in local disease extension.\(^1\)\(^-\)\(^2\) In addition to eliminating symptoms of benign prostatic hyperplasia (BPH), there is better molecular and cellular study of disease behavior, external conformational radiotherapy complications are avoided, and oncological control varies from 75-90% for the first 5 years, and 65-70% at 15 years.\(^4\)\(^-\)\(^5\) Several series have also demonstrated that the psychosocial impact from knowing that the tumor was completely extirpated has improved patient confidence and in turn, quality of life.\(^6\) It is most relevant to know how these parameters, in regard to knowledge of the disease and procedure and disease monitoring in Mexico, compare on an international scale.

The objective of the present article is to share the experience in the authors’ medical center with CaP treatment and to report on the comparability of these results with published standards of surgical results as well as oncological disease follow-up.

## METHODS

A retrospective study of case records of 87 patients having undergone radical prostatectomy (RP) at the authors’ institution from April 2003 to August 2009 was carried out. The demographic results analyzed were: age, comorbidities, and pathological variables. Diagnosis was based on prostate specific antigen (PSA), Gleason score determination from transrectal biopsy of the prostate (TRBP) and preoperative positive lymph node probability. Variables of intraoperative and postoperative complications, surgery duration, transfusions, deep vein thrombosis, pulmonary thromboembolism episodes, and oncological follow-up were analyzed. The follow-up variables analyzed were disease stage, Gleason score of surgical specimen, positive margins, postoperative PSA, nadir, PSA doubling time, corroboration of positive lymph node suspicion, and biochemical failure development and management. Micturition parameters of incontinence index and bladder neck contracture were also analyzed.

## RESULTS

Eighty cases of patients having undergone radical prostatectomy (RP) were evaluated. Mean age was 61.5 years (46-74 year range). In 2003, four patients underwent repeat surgery and in 2007 this figure increased five-fold (Image 1).

The most frequent PSA value before surgery or at the moment of diagnosis was 6.2 ng/mL (75%).\(^11\)\(^-\)\(^14\)\(^\text{16}\) Gleason value in TRBP was (3 + 3) and there was
suspicion of positive lymph nodes in 7.5% of patients (according to Partin table). Predominant Gleason score in surgical specimen was 3 + 2. Four specimens (5%) had positive margins. There was correlation between Gleason TRBP value and final specimen in only 27%; 31% were underestimated and 42% were overestimated (Image 2).

Postoperative PSA was under 0.4 ng/mL in 92% of patients during the first year. 8% of them did not reach this nadir. At the end of the first year 92% of patients continued under the nadir and 8% continued in biochemical recurrence. There were a minimum of modifications in the second year with 90% of patients not going over the nadir and 10% in biochemical failure but under 1.5 ng/mL. In the third year of follow-up, PSA values of 90% of patients continued under the nadir but of the 10% in biochemical failure, two patients had PSA values above 1.5 ng/mL and scintigram revealed bone metastases in one patient. In the fourth year of follow-up 80% of patients had PSA values under 0.4 ng/mL and 20% were over that figure.

At five years, 75% of patients (60 patients) had unchanged PSA, 25% reached biochemical failure, but only 2 patients continued to have PSA above 1.5 ng/mL. The death of one of those patients was related specifically to prostate cancer (Image 3).

For the cases classified as biochemical failure and with positive bone scintigraf, one patient was treated with docetaxel and the other with intermittent androgen block with analgesics. There were positive lymph nodes after lymphadenectomy in 5% of the total sample. In the authors’ group there was 1 cancer specific death and 5 deaths in patients with cancer but who died from other causes. There was one intraoperative complication due to acute myocardial infarction and another due to pulmonary thromboembolism. Urethrevesical catheter was left in place for a mean 11.38 days. There was incontinence in 10% of patients and the mean interval of time for returning to continence was 4-6 months. Bladder neck contracture incidence was 22%. 1,4,7,8

**DISCUSSION**

Radical prostatectomy is the most commonly performed treatment for organ-confined disease in the authors’ hospital. In some individualized cases it is rescue and tumor load reduction procedure. The authors’ results showed it to be a feasible procedure because only 4 procedures were performed during the first year, whereas this figure had tripled by the fourth year, and half the total number of cases were operated on in the last two years. Thorough evaluation of each patient continues to be the best diagnostic resource and includes PSA, DRE and TRBP which are clinical and diagnostic elements for opportune disease detection14,16 so that the possibility of cure can be attained through radical prostate surgery. Hospital stay is not lengthy, allowing patients to return to their normal activities more quickly.

Unfortunately, blood loss continues to be one of the biggest disadvantages in retropubic surgery, along with resulting blood transfusion consequences.7,10

Intraoperative and postoperative complications are the same complications that can occur in any pelvic surgery and in the authors’ series they presented at a low percentage. Systemic arterial hypertension and diabetes mellitus are the two most frequent comorbidities associated with CaP.9

Variations in Gleason scores in TRBP and final specimen lead to questions about the technique and thoroughness with which the pathology specimen should be analyzed, given that the correlation percentage is minimal.18

Correlation was nearly 100% in patients that underwent lymphadenectomy because of suspicion of positive lymph nodes; these cases are patients that presented with recurrence or positive margins and biochemical failure as well as Gleason grade of poorly differentiated tumor. The more aggressive the tumor the less possibility of cure and prognosis is aggravated and disease-free survival is reduced. Clearly, the principal objectives and benefits of radical prostate surgery are to attempt to cure and to increase disease-free survival.4

Biochemical failure can be defined as PSA greater than 0.4 ng/mL immediately after surgery or two consecutive PSA elevations in relation to the nadir in less than six months (defining nadir as postoperative...
PSA value that is low but present in at least two samples within a one-year interval). However, evaluation of patients with biochemical recurrence is very complex and is a great challenge for the urologist.13-19, 23-26

Finally, incontinence rate is dramatically reduced when the technique is perfected and disease is slight or moderate. Bladder neck contracture continues to be the most frequent postoperative consequence but it does not represent a technical challenge for the surgeon and fortunately is a low surgical risk for the patient.1,5,7,8,11

CONCLUSIONS

Radical surgery of the prostate is the most widely used therapy in the authors’ medical center for treating organ-confined CaP. Reproducibility and the perfecting of this technique have provided tangible surgical results (shorter hospital stay, reduction of intraoperative complication rate, better vascular control and thus lower blood transfusion rate and reduction of intraoperative hemorrhage). The attained oncolgical results are reflected in better patient selection, reduction of positive margins,22 and early identification of high risk patients for metastatic progression or nodular disease.

The European Association of Urology guidelines state that all patients presenting with biochemical failure, whose PSA level is not above 1.5 ng/mL and who present with negative bone scintigram, can be conservatively managed with surveillance and have a disease-free life comparable to that of low-risk patients. Therefore the authors believe that the oncolgical results of their series are very satisfactory and offer their treatment group a disease-free life similar to that reported in experienced centers in the United States and Europe.

In addition bladder function is respected in the large majority of patients.

BIBLIOGRAPHY

2. Richie JP. Radical prostatectomy vs watchful waiting in early prostate cancer. BJU Int. 2005 Nov;96(7):951-2
12. Allibhai SM, Leach M, Tomlinson G. Examining the location and cause of death within 30 days after radical prostatectomy. BJU Int. 2005 Mar;95(4):541-4